Lipocine (NASDAQ:LPCN) Rating Lowered to “Hold” at StockNews.com

StockNews.com downgraded shares of Lipocine (NASDAQ:LPCN) from a buy rating to a hold rating in a research report released on Thursday.

Separately, Alliance Global Partners assumed coverage on Lipocine in a research report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective on the stock.

Lipocine Trading Down 12.7 %

NASDAQ:LPCN traded down $0.71 during mid-day trading on Thursday, hitting $4.88. The company had a trading volume of 62,976 shares, compared to its average volume of 47,286. The business has a fifty day simple moving average of $4.85 and a 200-day simple moving average of $5.62. Lipocine has a 1 year low of $2.35 and a 1 year high of $11.79. The firm has a market capitalization of $26.11 million, a price-to-earnings ratio of -3.21 and a beta of 1.18.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter. The business had revenue of $0.09 million during the quarter. As a group, research analysts anticipate that Lipocine will post -0.92 earnings per share for the current year.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in shares of Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission (SEC). 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.